The Efficacy of Tamsulosin Monotherapy and Its Combination with Mirabegron for Overactive Bladder Induced by Benign Prostatic Hyperplasia
Abstract
Alpha 1 adrenoceptor antagonists such as (tamsulosin) are developed for treating of overactive bladder (OAB) associated with benign prostatic hyperplasia (BPH), Acting by blockage of adrenoceptors so can cause relaxation of smooth muscle of the bladder neck and prostate, resulting in an improvement in urine flow and reduction in lower urinary tract symptoms (LUTS). Recently the beta-3 adrenoceptor agonist (mirabegron) has been shown to treat the(OAB) symptoms act by relaxation of detrusor smooth muscle of the bladder, increase the bladder capacity and minimize lower urinary tract symptoms (LUTS) that is associated with (BPH) with less side effect than other pharmacotherapies. We will study the efficacy and safety of this combination therapy.
To compare the efficacy and safety of the combination therapy mirabegron and tamsulosin versus tamsulosin monotherapy in case of overactive bladder associated with benign prostatic hyperplasia.
this prospective randomized controlled study conducted in 60 patients between ages of 50-70years and complaining of lower urinary tract symptom(LUTS) associated with(BPH) benign prostatic hyperplasia, Before and 12 weeks after mirabegron additional therapy (50 mg once daily), we evaluated the efficacy of this treatment using the Overactive Bladder Symptom Score (OABSS) and International Prostate Symptom Score (IPSS), and changes in the maximum flow rate (Qmax) and post-void residual urine volume (PVR).
60 men were enrolled in this study. The…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 60 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.